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Objective: To determine whether prospective testing for HLA-B*58:01, as a strategy to 
prevent serious adverse reactions to allopurinol in patients with gout, is cost-effective from 
the perspective of the National Health Service in the UK. 
Methods: A systematic review and meta-analysis for the association of HLA-B*58:01 with 
cutaneous and hypersensitivity adverse drug reactions (ADRs) informed a decision analytic 
and Markov model to estimate lifetime costs and outcomes associated with testing versus 
standard care (with febuxostat prescribed for patients who test positive). Scenario analyses 
assessed alternative treatment assumptions and patient populations. 
Results: The number of patients needed to test to prevent one case of ADR was 11,286 (95% 
Central Range, CR 2,573, 53,594). Cost and quality-adjusted life-year (QALY) gains were 
small £103 (95% CR £98, £106) and 0.0023 (95% CR -0.0006, 0.0055), resulting in an 
incremental cost-effectiveness ratio (ICER) of £44,954 per QALY gained. The probability of 
testing being cost-effective at a threshold of £30,000 per QALY was 0.25. Reduced costs of 
testing or febuxostat resulted in an ICER below £30,000 per QALY gained. The ICER for 
patients with chronic renal insufficiency was £38,478 per QALY gained.  
Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse 
drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-
effective in the UK; however testing is expected to become cost-effective with reductions in 
the cost of genotyping, and with the future availability of cheaper, generic febuxostat. 
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Gout is a common inflammatory condition characterised by acute attacks (flares) which are 
episodes of severe joint pain, usually with redness, swelling, and tenderness of the joint; 
and is associated with increased risk of cardiovascular disease [1, 2]. Gout affects 
approximately 2.5% of the population and is most prevalent in older men [3]. 
Standard treatment for the long term management of gout includes urate lowering agents, 
with allopurinol accounting for 89% of prescriptions in the UK between 2000 and 2005 [4].  
Allopurinol is generally well tolerated, but is associated with rare but severe cutaneous 
adverse drug reactions (SCARs) including Steven-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TEN), affecting approximately 7 in 10,000 patients [5]. SCARs are 
associated with high mortality – up to 30% in the case of TEN [6]. Allopurinol is also 
associated with hypersensitivity adverse drug reactions (ADRs) (hereafter referred to as 
drug reaction with eosinophilia and systematic symptoms (DRESS)), including drug induced 
hypersensitivity syndrome (DIHS), also sometimes called allopurinol hypersensitivity 
syndrome (AHS) or hypersensitivity syndrome (HSS) [7]. 
Genetic association studies have identified the presence of the HLA-B*58:01 allele to be an 
important risk factor for allopurinol-induced SJS or TEN, with an odds ratio of 96.6 (95%CI 
24.5, 381.0) [8]. HLA-B*58:01 is present in 15% to 18% of certain Asian populations but is 
less common (1% to 2%) in European populations [9]. Other risk factors for allopurinol 
hypersensitivity include high dose, renal impairment and concomitant use of diuretics [10]. 
While routine testing is not currently recommended by the Food and Drug Administration or 
the European Medicines Agency [11], the American College of Rheumatology guidelines 
note that genotyping should be considered in selected patients at elevated risk of ADRs, 
5 
 
including those with chronic renal insufficiency [12]. There are no randomised controlled 
trials of routine testing; however prospective cohort studies have suggested effectiveness in 
Taiwanese populations [13], and Korean patients with chronic renal insufficiency [14]. In 
both studies, patients who tested positive for HLA-B*58:01 either avoided allopurinol or 
were administered allopurinol on a 28-day induction programme. No cases of SCAR 
occurred in either study, compared with expected rates of 0.3% [13] and 18% [14]. 
Many healthcare systems require evidence of efficiency for broader adoption of health 
technologies, including pharmacogenetics tests. Existing economic analyses have indicated 
that genotyping for HLA-B*58:01 may be cost-effective in both Thailand and Korea [15, 16], 
but not in Singapore [17].  
The aim of the present analysis is to estimate the cost-effectiveness of HLA-B*58:01 
genotyping prior to prescription of allopurinol in the UK healthcare setting. 
Methods 
Overview 
A cohort model was used to track patients with chronic gout over a lifetime. Patients either 
receive allopurinol, or are first genotyped for HLA-B*58:01 before being prescribed either 
allopurinol or febuxostat, conditional on test result. Febuxostat is recommended by the 
National Institute for Health and Care Excellence (NICE) in the UK as a second line treatment 
if allopurinol is not tolerated or is contraindicated. The analysis adopts the costing 
perspective of the National Health Service (NHS) in the UK assuming cost year 2014. Health 
outcomes were measured as quality-adjusted life-years (QALYs). Costs and QALYs were 
discounted after 1 year at a rate of 3.5% per annum. The base-case population was chosen 
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to be representative of the gout population in the UK, 81% male, with a mean age at 
diagnosis of 61.6 years [4]. 
The model, which is depicted in Figure 1, was adapted from the decision analysis of Beard et 
al [18] (2014), incorporating 3-month decision trees to capture the time during which the 
majority of serious ADRs are likely to occur [5, 19]. A Markov model, with a cycle length of 3 
months and with half-cycle correction, captured the lifetime sequelae of SJS,TEN and DRESS, 
and the long term differences in costs and effectiveness of alternative urate lowering 
agents. States within the model were defined according to: (i) serum uric acid (sUA) 
concentration < 360µmol/l, (ii) 360µmol/l < sUA < 475µmol/l, (iii) 475µmol/l < sUA < 
595µmol/l and (iv) sUA > 595µmol/l, and reflect whether patients had experienced SJS, TEN 
or DRESS, with an option for (v) acute flares, and (vi) death (Figure 1). We assumed sUA to 
remain constant for individual patients, based on data from the EXCEL study, which 
indicated that 75% to 100% of patients who achieved sUA < 360µmol/l maintained this over 
the remainder of the study [20]. 
*insert figure 1 here* 
Treatment pathway 
For standard care, all patients are prescribed allopurinol, titrated to 300mg/day during the 
first 3 months. Patients who are genotyped for HLA-B*58:01 or who experience a serious 
ADR with allopurinol switch to febuxostat 80mg/day, given there is no evidence of cross-
reactivity [21, 22]. Patients experiencing a serious ADR with febuxostat (which are far less 
likely) [23], discontinue urate lowering therapy altogether.  
7 
 
The clinical effectiveness for allopurinol, febuxostat and symptomatic flare management 
was considered in terms of the endpoint of reducing sUA to < 360µmol/l; consistent with 
existing clinical guidelines for the management of gout [12, 24, 25], and in terms of 
prevention (or in the prophylaxis period, provocation) of gout flares.  Prophylactic treatment 
with colchicine (500μg twice daily) was modelled for 3 months following initiation of 
allopurinol, or for 6 months following initiation of febuxostat [26]. The use of NSAIDs is 
assumed for all patients; but not probenecid, which is not listed in the British National 
Formulary. 
Model parameters 
Parameter estimates were obtained from purposive reviews of the literature and are listed 
in Table 1.  
*table 1 here* 
Clinical effectiveness 
The risk-ratios for sUA < 360µmol/l with febuxostat 80mg/day and allopurinol 300mg/day 
were taken from the Cochrane review and meta-analysis based on data from the FACT [30], 
APEX [30], and CONFIRMS [31] trials. The risk-ratio for achieving sUA to < 360µmol/l with no 
treatment was taken from the Cochrane review and meta-analysis of studies comparing 
allopurinol 300mg/day and placebo [27]. 
For patients who did not achieve sUA < 360µmol/l, the distribution of patients across the  
‘non-response’ sUA categories was allocated according to those indicated in Beard et al [18], 
taken from the FACT and APEX studies [29, 30].The distribution of patients across sUA 
categories for no treatment was assumed to be the same as for allopurinol. 
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The probability of experiencing a flare during prophylaxis  was taken from a pooled analysis 
of 8-week data from the FACT [29], APEX [30], and CONFIRMS trials [31] for allopurinol; and 
from a Cochrane review for febuxostat [28]. For subsequent model cycles, and for patients 
who were not prescribed urate lowering treatment, the probability of flares was determined 
by sUA concentration, as in Beard et al [18]. 
Prevalence of allopurinol induced SJS, TEN or DRESS 
With a background population incidence of SJS/TEN of between 0.4 and 6 persons per 
million per year [15], and a risk ratio for allopurinol-induced SJS/TEN within the first 2 of 
initiation of 52 [19], the incidence of allopurinol induced SJS/TEN was calculated as being 
between 0.2 and 3 cases per 10,000 patients. Within the model we use a mean point 
estimate of 1.6 cases per 10,000 patients. 
Data for DRESS were taken from a study of 1835 patients who were prescribed allopurinol, 
while monitored in a drug surveillance program [37]. 
Association between HLA-B*58:01 and allopurinol induced SJS, TEN or DRESS 
The systematic review by Somkura et al [8] was updated using PubMed (from inception up 
until August 2016) using the search terms (“HLA-B” OR “Human leukocyte antigen”) AND 
“allopurinol” AND (“Stevens Johnson Syndrome” OR “Toxic Epidermal Necrolysis” OR “Drug 
Reaction with Eosinophilia and Systematic Symptoms” OR “Drug Induced Hypersensitivity 
Syndrome” OR “Hypersensitivity Syndrome” OR “Allopurinol Hypersensitivity Syndrome”) or 
their acronyms. Search results were cross-referenced against the allelefrequencies database 
of studies of the association between HLA-B*58:01 and allopurinol-induced ADR [9]. Studies 
were eligible for meta-analysis if they included an allopurinol tolerant control.  
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Meta-analysis was conducted using the metandi hierarchical logistic regression package in 
STATA (version 13; StataCorp LP, College Station, TX) [38] to determine the pooled 
sensitivity and specificity of the presence of HLA-B*58:01 in predicting allopurinol induced 
SJS, TEN and DRESS. 
Thirteen articles qualified for the meta-analysis (Appendix 1, 2). The pooled sensitivity of the 
13 SJS/TEN studies was 0.95 (95% CI 0.90, 0.97), with specificity 0.88 (95% CI 0.84, 0.91). 
Meta-analysis of data from 10 DRESS studies resulted in a pooled sensitivity of 0.93 (95% CI 
0.84, 0.98) and specificity 0.85 (95% CI 0.65, 0.94).  
Based on the prevalence of allopurinol induced SJS/TEN and DRESS, the positive predictive 
value (PPV) of genotyping for SJS/TEN is 0.0013, whilst the negative predictive value (NPV) 
of genotyping for SJS/TEN is 1.000. The corresponding values for DRESS are 0.0067 and 
0.9999, respectively. 
Allele prevalence 
Pooled data for European populations (not restricted by ethnicity) resulted in an allele 
prevalence of 1.13% (95% CI 1.08%, 1.19%) [9].  
Health state utilities  
There is limited evidence linking health state utility with sUA concentrations or incidence of 
flares [39]. To date, all EQ-5D data reported in published economic evaluations have been 
sourced from an unpublished study of 417 patients from the UK, Germany and France [4, 
18]. In the absence of alternative data, we assumed the same relationship of health utility 




Utility decrements corresponding to SJS/TEN and DRESS were assigned as for severe burns 
[33] and sepsis [35], respectively, consistent with other economic evaluations [17, 36, 40]. 
Longer term disutilities to capture long term sequelae for SJS, TEN and DRESS (applied to the 
model from 3-months post ADR onwards) were taken from patient-level data for survivors 
of TEN [34].  
Mortality 
All-cause mortality was taken from UK life tables [32], adjusted by age and gender, whilst 3-
month mortality for SJS/TEN and for DRESS were modelled at 26.5% (95% CI 18%, 24%) [6] 
and 10% (95% CI 5%, 15%) [7], respectively. 
Costs 
The total cost of gout maintenance treatment (£97.40 for 3 months) included consultation 
with General Practitioner, diagnostic tests (including sUA, serum creatinine and renal 
function), procedures (X-rays and joint aspiration) and hospitalisation due to complications 
of gout such as urinary tract infections or renal stones [18]. The total cost of flare 
management (£321.62 for the immediate treatment and management of an acute flare) 
included the costs of inpatient hospitalisation and outpatient clinic visits. The cost of 
allopurinol, febuxostat and colchicine were based on daily doses of 300mg (titrated over the 
course of the first cycle), 80mg and 1mg, respectively [26].   
The costs of the acute management of SJS/TEN and DRESS reactions were based on a 
previous economic evaluation [36], in which data on healthcare resource use (e.g. 
treatments, procedures, length of hospitalisation according to intensity of care) were 
identified from a systematic review of the literature, and costed using NHS unit costs. We 
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found no evidence for the cost of long term management of SJS/TEN and so assumed that 
patients would require follow-up consultant appointments, which were costed based on 1 
hour per annum. We further assumed there would be no cost incurred for managing 
sequelae of DRESS.  
The cost of genotyping was based on a 2-stage process; an initial screen for HLA-B*58 
(£54.29) and, in patients who test positive, a second high resolution test for the specific 
HLA-A*58:01 allele (£94.91) [36]. 
Analysis 
Costs and QALYs were summed for genotyping prior to initiation of the urate lowering 
therapy, and for standard care (prescription of allopurinol without genotyping). The 
incremental cost-effectiveness ratio (ICER) was calculated as: 
ICER =
Costwith test - Coststandard care: no test
Outcomewith test - Outcomestandard care: no test
 
The economic evaluation was analysed in Microsoft Excel 2013, and reported according to 
the Consolidated Health Economic Evaluation Reporting Standards [41]. 
 
Sensitivity analysis 
Parameter uncertainty was assessed by varying each parameter within its 95% confidence 
interval or, if unavailable, within a plausible range which, in the case of costs, was based on 
a standard deviation of 25% of the mean (Table 1).  
A probabilistic sensitivity analysis was performed using a Monte Carlo simulation with 
10,000 replications, and a cost-effectiveness acceptability curve (CEAC) constructed to 
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depict the probability of genotyping being cost-effective for a range of cost-effectiveness 
thresholds [42].  
Scenario analysis 
A scenario reflecting a single stage testing process was considered, at a cost of £20 per test. 
In order to simulate future price reduction of febuxostat, as may result following patent 
expiry, we explored the impact of equating the cost of febuxostat to that of allopurinol. We 
also present results from the first six months, corresponding with the time period where 
adverse events are most likely to occur. 
We developed a scenario analysis which considered the case where patients experiencing 
SJS/TEN or DRESS with either allopurinol of febuxostat are treated symptomatically, which 
may reflect patients’ reluctance to take further medicines following a serious adverse drug 
reaction [43].  
We also assessed alternative scenarios for patients who test positive for HLA-B*58:01. 
Firstly, we considered such patients to be treated symptomatically, without maintenance 
uric acid lowering treatment, which may reflect a patient preference to discontinue 
treatment [44]. Secondly, we considered the scenario in which allopurinol would continue 
to be prescribed but that patients would be monitored closely. In this scenario, we assumed 
monitoring would also take place in patients prescribed febuxostat or symptomatic 
treatment, following experience of SJS/TEN or DRESS. Whilst the incidence of SJS/TEN or 
DRESS will not be affected by increased monitoring, early discontinuation of causative drug 
has been shown to improve mortality outcomes, with odds ratio 0.69 per day [45]. The cost 
of the monitoring service was based on 20 minutes of a pharmacist’s time, costed at £71 per 
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hour, to allow for additional information at initiation, and two follow up phone calls during 
the first 6 months [46].  
A scenario analysis which limits testing to patients with chronic renal insufficiency was 
assessed given this being an independent risk factor for SJS/TEN and DRESS in patients 
prescribed allopurinol, (relative risk compared with no chronic renal insufficiency 3.79; 95% 
CI 2.43, 5.92) [30]. Patients with chronic renal insufficiency (eGFR 15-29 mL/min/1.73m2) 
have a standardised mortality ratio of 3.2 (95% CI 3.1, 3.4) [25], and SJS/TEN is associated 
with increased mortality in this patient group (67% of patients experiencing SJS/TEN do not 
survive the ADR) [30]. The increased prevalence of SJS/TEN and associated mortality were 
modelled alongside reduced dose of allopurinol (100mg per day) and reduced dose 
colchicine (0.5mg per day) as recommended for this population [26].  
As being female is associated with a higher risk of allopurinol induced SJS/TEN or DRESS (OR 
1.45; 95% CI, 1.35-1.56) [9, 47], and that SJS/TEN and DRESS mortality is higher in females 
(OR 1.63; 95% CI, 1.28-2.08) [47] we conducted an analysis for a female population 
subgroup, aged 62.  
Whilst the primary analysis is for a European population, the population of the UK is 
ethnically diverse. We conducted an analysis which considered an increased prevalence of 
HLA-B*58:01, based on a pooled analysis of populations of Asian ethnic origin, at 4.24% [9]. 
A further analysis was considered for the population with greatest prevalence of HLA-
B*58:01, at 17% (the China Guangdong Province Meizhou Han population) [9]. 
Finally, as the long term impact of alternative treatments and the long term consequences 
of SJS/TEN or DRESS will have a greater lifetime impact on younger populations, we tested 







The modelled rate of ADRs in the test group was 0.95 (95% central range [CR] (0.16, 3.04)) 
per 10,000 patients, compared with 1.83 (95% CR 0.40, 6.00) in the standard care group. 
The number needed to screen in order to prevent one ADR (either SJS/TEN or DRESS) is 
11,286 (95% CR 2,573, 53,594). 
There is a small, but significant, incremental cost of £103 (95% CR £98, £106) associated 
with testing (Table 2). Cost differences are mainly attributable to drug costs and the cost of 
genotyping. There is also a very small QALY gain from testing, of 0.0023 (95% CR -0.0006, 
0.0055), however this is not significant. QALY gains predominantly derive from better 
management of gout as febuxostat is more efficacious than allopurinol. The resulting ICER 
for HLA-B*58:01 genotyping was £44,954 per QALY gained.  
*insert table 2 here* 
Parameter and structural sensitivity analysis 
A tornado plot illustrating the sensitivity of the ICER to the 10 most influential parameters is 
shown in Figure 2. Univariately, the efficacy of febuxostat (risk ratio for achieving sUA < 
360µmol/l versus allopurinol) and the cost of genotyping were most influential. The ICER 
was stable to variation in all other parameters within their 95% confidence interval. 
Figure 3 presents the CEAC for the base case analysis, which indicates that the probabilities 
of genotyping being cost effective at ceiling ratios of £20,000 and £30,000 per QALY are 0.05 
and 0.25, respectively.  
*insert figures 2 and 3 here* 
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Scenario analyses (Table 3), indicate testing to be cost-effective within populations with a 
higher prevalence of HLA-B*58:01 (at £27,218 and £22,359 per QALY gained, for 4.24% and 
17% prevalence, respectively) where the number needed to screen to prevent one ADR 
reduces to 3,018 and 753; and when the cost of febuxostat is reduced to that of allopurinol, 
resulting in an ICER of £23,679 per QALY gained. A less expensive, single-stage test, reduces 
the ICER to £29,469 per QALY gained. In the case of both reduced price febuxostat and 
cheaper testing, the ICER is £8,195 per QALY gained.  
*insert table 3 here* 
Blanket prescription of allopurinol with only symptomatic treatment following ADR resulted 
in a reduction in both costs and QALYs. For other scenarios, and alternative modelling 
assumptions, ICERs remained higher than £30,000 per QALY. While the number needed to 
screen to prevent one case of SJS/TEN in patients with chronic renal insufficiency reduced to 
2,964, testing remained not cost-effective at £38,478 per QALY gained. Based on a 12-
month time horizon of analysis, the QALY gain, being almost solely attributable to the 





Our model suggests that from a UK NHS perspective, routine genotyping for HLA-B*58:01 is 
not cost-effective for preventing SJS/TEN and DRESS associated with allopurinol in patients 
with gout. The small QALY gain, equivalent to less than one quality-adjusted day, is 
commonplace in pharmacogenetic testing due to the low allele prevalence and rarity of the 
adverse event leading to a low PPV [48]. In scenario analyses, genotyping was modelled to 
be cost-effective when the price of testing reduced to ≤£21 per patient, or when the cost of 
febuxostat is reduced, such as might be expected once available generically, expected in 
2019. The model was robust to the alternative assumption of no uric acid lowering 
treatment being prescribed following a serious ADR, which may reflect patient or prescriber 
preference [43]. 
We are aware of three existing economic evaluations of HLA-B*58:01 screening for 
preventing allopurinol induced SCAR, with mixed results of cost-effectiveness [15, 16, 17]. 
Differences among these studies can be attributed to differences in populations but also 
methodological limitations which are addressed in our analysis. 
Firstly, our analysis has strength in the use of febuxostat as a realistic and licensed 
comparator to allopurinol for a UK setting. Of the previously conducted economic 
evaluations, only Park [16] considered febuxostat as a comparator; both other studies 
consider probenecid as the comparator [15, 17], which has very limited use in the UK.  
Secondly, previous economic evaluations made no consideration of the relative 
effectiveness of urate lowering drugs, and focused exclusively on differences in the rates of 
SCAR. The Thai analysis, for instance, assumed a single health utility applied to all patients 
regardless of treatment received [15]. This represents a major limitation, as febuxostat may 
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be more effective than allopurinol in lowering serum urate, if not in reducing the incidence 
of gout flares or tophus area [40]. By adopting a lifetime horizon of analysis that captured 
the differences in efficacy and costs between treatments, our analysis reduces this bias 
while also taking fully into account the long term sequelae of SJS/TEN and DRESS. 
Only one previous economic evaluation has considered hypersensitivity reactions other than 
SJS/TEN [17], and we are the first to consider SJS/TEN and DRESS separately.  
Our analysis also benefited from having modelled a number of potential patient 
populations, to reflect different clinical circumstances where genotyping may be cost-
effective, as well as different scenarios of drug sequences in patients who experience ADRs 
and future decreases in the cost of testing and febuxostat.  
As with any economic model, however, we were reliant on disparate sources of evidence 
and some assumptions were necessary. Firstly, we relied on unpublished data on utilities in 
gout. Alternative, published data of EQ-5D utilities in 110 patients, did not present utility by 
drug, disease severity or response to treatment, and were therefore unsuitable for 
populating the model [49]. However the mean utility value of 0.74 (SD 0.23) is consistent 
with the data used in our analysis.  
Secondly, our analysis did not capture any adverse events other than SJS/TEN or DRESS, 
which may have implications, especially in chronic renal populations. Neither were other 
common comorbidities, such as cardiovascular disease and diabetes taken into account 
explicitly. However, with the assumption that the populations from which costs and utilities 
were sourced, were representative of a general gout population, such comorbidities would 
have been captured implicitly. 
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Thirdly, the scenario representing patients with chronic renal insufficiency did not account 
for costs or QALYs associated with the condition, but only the impact of the condition on 
SJS/TEN and DRESS, mortality and prescription costs. Moreover, there was no evidence as to 
whether the rate of SJS/TEN or DRESS in febuxostat treated patients with chronic renal 
insufficiency would be any higher than in the general population. 
Fourthly, in the absence of data, we assumed that the probability of an increase in flares 
during the prophylaxis period is independent of the probability of achieving sUA < 
360µmol/l.  
Finally, we assumed that sUA remains constant after 12 weeks provided that treatment 
does not change. This is consistent with other economic evaluations [17, 18], and with 
results from the EXCEL study [20], but requires patients to be fully adherent, which may not 
be the case in practice [44].  The EXCEL study noted that after 24 months, 76% of patients 
prescribed febuxostat remained on treatment, whilst only 40% of patients persisted with 
allopurinol [20]. 
In conclusion, our analysis suggests that routine, prospective genotyping for HLA-B*58:01 
prior to the prescription of allopurinol for gout is not cost-effective in a UK NHS setting. 
There are, however, subpopulations where testing is more likely to be cost effective, 
including patients with chronic renal insufficiency, and populations with a higher HLA-
B*58:01 prevalence. Testing is expected to become cost-effective with reductions in the 




 HLA-B*58:01 is associated with severe adverse drug reactions to allopurinol in patients 
with gout. 
 Routine testing of gout patients for HLA-B*58:01 is currently not cost-effective in the UK. 
 HLA-B*58:01 genotyping of gout patents is cost-effectiveness if the price of testing and 
febuxostat reduces. 
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Table 1: Model inputs: Transition probabilities, costs and utilities 










 Prevalence of HLA-B*58:01 (European 
mean) 
0.0113 Beta(27340, 202446) 0.0108 0.0119 [9]  
 P(SJS/TEN|allopurinol) within 3 months 
of initiation 
0.0002 Normal(0.0002, 0.00007) 0.00002 0.0003 [15, 19]  
 P(DRESS|allopurinol) within 3 months 0.0011 Beta(2, 1835) 0.0001 0.0030 [26]  
 P(SJS/TEN| febuxostat) within 3 months 
of initiation 
0.00010 Beta(1, 9999) 0.00000 0.00037 [23]  
 P(DRESS| febuxostat) within 3 months of 
initiation 
0.00010 Beta(1, 9999) 0.00000 0.00037 [23] 
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 Sensitivity of test (SJS/TEN) 0.9285 Beta(144.64, 8.07) 0.8984 0.9732 Meta analysis 
 Specificity of test (SJS/TEN) 0.8907 Beta(311.64, 42.01) 0.8432 0.9110 Meta analysis 
 Sensitivity of test (DRESS) 0.9348 Beta(56.34, 3.93) 0.8387 0.9753 Meta analysis 
 Specificity of test (DRESS) 0.8470 Beta(20.51, 3.63) 0.6544 0.9441 Meta analysis 
 P(360µmol/l | allopurinol) 0.3800 Beta(497.8, 812.2) 0.3539 0.4064 [27]  
 Proportion of non-responders with  
(360µmol/l < sUA < 475µmol/l| 
allopurinol) 
0.7900 Beta(641.638, 170.562) 0.7613 0.8173 [18]  
 Proportion of non-responders with  
(475µmol/l < sUA < 595µmol/l | 
allopurinol) 
0.1750 Beta(142.135, 670.065) 0.1497 0.2019 [18] 
 Proportion of non-responders with  (sUA 
> 595µmol/l | allopurinol) 
0.0350 Beta(28.247, 783.773) 0.0235 0.0487 [18] 
 Risk ratio UA febuxostat vs allopurinol 1.8182 Gamma(208.2823, 0.0088) 1.5873 2.0833 [28]  
 P(360µmol/l| febuxostat) 0.6909    RR*allopurinol  
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 Proportion of non-responders with  
(360µmol/l < sUA < 475µmol/l | 
febuxostat)  
0.7410 Beta(299.5796, 104.7113) 0.6973 0.7825 [18]  
 Proportion of non-responders with  
(475µmol/l < sUA < 595µmol/l | 
febuxostat)  
0.2130 Beta(86.114, 318.177) 0.1745 0.2542 [18] 
 Proportion of non-responders with  (sUA 
> 595µmol/l | febuxostat)  
0.0460 Beta(18.597, 385.694) 0.0278 0.0684 [18] 
 Risk risk sUA none vs allopurinol 0.0203 Gamma(0.0898, 0.1586) 0.0029 0.1439 [27]  
 Proportion of non-responders with  
(360µmol/l < sUA < 475µmol/l| no 
treatment)  
0.7900 Beta(641.638, 170.562) 0.7613 0.8173 As for allopurinol 
 Proportion of non-responders with  
(475µmol/l < sUA < 595µmol/l | no 
treatment)  
0.1750 Beta(142.135, 670.065) 0.1497 0.2019 As for allopurinol 
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 Proportion of non-responders with  (sUA 
> 595µmol/l | no treatment)  
0.0350 Beta(28.247, 783.773) 0.0235 0.0487 As for allopurinol 
 P(initial flares | allopurinol) 0.1402 Beta(166, 1184) 0.1210 0.1605 [29, 30, 31]  
 Risk ratio of initial flare, febuxostat vs 
allopurinol 
1.3130 Gamma(43.2461, 0.0311) 0.9730 1.7720 [28]  
 P(acute flares | sUA < 360µmol/l) 0.0874 Beta(311.5008,3252.5819) 0.0784 0.0969 [18]  
 P(acute flares | 360µmol/l < sUA < 
475µmol/l) 
0.0989 Beta(307.8354,2804.7567) 0.0887 0.1096 [18] 
 P(acute flares | 475µmol/l < sUA < 
595µmol/l) 
0.1085 Beta(304.4738, 2501.7361) 0.0973 0.1203 [18] 
 P(acute flares  | sUA > 595µmol/l) 0.1161 Beta(301.9822, 2299.0704) 0.1041 0.1287 [18] 
 Mortality *  Assumed fixed as based on entire population [32]  
 Mortality: SJS/TEN 0.2652 Beta(122, 338) 0.2259 0.3065 [6]  




 *Gout with sUA < 360µmol/l 0.7463 1-Beta(98.9914, 291.1993) 0.7020 0.7882 [18]  
 *Gout with 360µmol/l < sUA < 475µmol/l 0.7120 1-
Beta(121.7288,300.9406) 
0.6680 0.7541 [18] 
 *Gout with 475µmol/l < sUA < 595µmol/l 0.6777 1-
Beta(145.1274,305.1592) 
0.6339 0.7200 [18] 
 *Gout with sUA > 595µmol/l 0.6435 1-
Beta(168.6184,304.3645) 
0.5998 0.6860 [18] 
 Disutility: Gout flare 0.0097 Beta(15.8351, 1616.6494) 0.0055 0.0150 [18]  
 Disutility: SJS/TEN – acute 0.1400 Gamma(3.7867, 0.1901) 0.1869 1.6054 [33]  
 Disutility: SJS/TEN – long term 0.1149 Gamma(0.4423, 0.2597) 0.0000 0.6102 [34]  
 Disutility: DRESS - acute 0.1430 Gamma(0.9086, 0.1574) 0.0026 0.0121 [35]  
 Disutility: DRESS – long term 0.1149 Gamma(0.4423, 0.2597) 0.0000 0.6102 [34]  
Resource use and costs 
 Cost: Gout flare 321.62 Gamma(16, 20.1011) 183.83 497.31 [18]  
 Cost: Gout maintenance 97.40 Gamma(16, 6.0874) 55.67 150.60 [18] 
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 Cost: Allopurinol 300mg 3.77 Fixed 3.41 4.15 [26]  
 Cost: Febuxostat 80mg 79.17 Fixed 71.60 87.11 [26] 
 Cost: Colchicine 1mg (500 microgram 
BID) 
65.92 Fixed 59.62 72.54 [26] 
 Cost: SJS/TEN – acute 31,232.00 Gamma(1.18, 25262.51)  1,626.72 103,207.86 [36]  
 Cost: SJS/TEN – long term 140.00 Gamma(3.84, 42.17) 0.00 280.00 Expert opinion 
 Cost: DRESS - acute £11,209.03 Gamma(7.44, 1507.13)) £4658.78 £20,585.50 [36]  
 Cost of HLA-B*58 screen 54.29 Fixed 10.00 90.00 [36]  
 Cost of HLA-B*58:01 94.91 Fixed 30.00 150.00 [36] 
Abbreviations: SJS Steven-Johnson syndrome, TEN toxic epidermal necrolysis, DRESS drug reaction with eosinophilia and symptomatic 
symptoms, P probability, sUA serum uric acid concentration, RR risk ratio, BID twice a day 




Table 2: Results of the base-case analysis 
 Test Standard care Incremental 
 Cost QALYs Costs QALYs Costs QALYs 
Gout management £5,597 10.3400 £5,596 10.3378 £0.06 0.0022 
Gout flare management (prophylaxis) £45.26 -0.0003 £45.10 -0.0003 £0.16 0.0000 
Gout flare management (non-
prophylaxis) £1,741 -0.0131 £1,742 -0.0131 -£0.82 0.0000 
Treatment of SJS/TEN and DRESS £1.27 -0.000004 £2.53 -0.000012 -£1.26 0.0000 
Managing sequelae of SJS/TEN and 
DRESS £0.06 -0.0001 £0.14 -0.0003 £-0.08 0.0001 
Genotyping £55.50  £0  £55.50  
Drug cost £333.79  £284.30  £49.49  
Total £7,773 10.3264 £7,671 10.3241 £103.05 0.0023 
Abbreviations: SJS Steven-Johnson syndrome, TEN toxic epidermal necrolysis, DRESS drug reaction with eosinophilia and symptomatic 
symptoms, QALY quality-adjusted life-year   
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to screen to 
prevent one ADR  
ICER 
(Cost/QALY) 
Base case £103.05 0.0023 11,286 £44,954 
Results at 6 months £56.81 0.0001 11,286 £706,624 
35 year old male £128.68 0.0035 11,286 £36,571 
62 year old female £107.06 0.0026 10,437 £41,176 
Chronic renal insufficiency* £84.46 0.0022 2,964 £38,478 
Prevalence of HLA-B*58:01 4.24% £233.34 0.0086 3,018 £27,218 
Prevalence of HLA-B*58:01 17% £768.55 0.0344 753 £22,359 
Set comparator ULA cost equal to allopurinol** £54.28 0.0023 11,286 £23,679 
Single stage test, cost £20 £67.55 0.0023 11,286 £29,469 
All prescribed allopurinol. No ULA in case of 
ADR 
-£0.72 -0.0001 ***  £11,081^  
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Test negative: Allopurinol; Test positive: 
Febuxostat; No ULA in case of ADR 
£102.69 0.0023 11,284  £45,456 
Test negative: Allopurinol; Test positive: No 
ULA; No ULA in case of ADR 
£51.18 -0.0024 11,003 Dominated 
Test negative: Allopurinol; Test positive: 
Allopurinol with increased monitoring; 
Febuxostat in case of ADR 
£55.82 0.0000 *** £1,783,994 
Abbreviations: QALY quality-adjusted life-year, ICER incremental cost effectiveness ratio, ADR adverse drug reaction, ULA urate lowering agent, 
PPV positive predictive value, NPV negative predictive value 
*Chronic renal insufficiency: SJS/TEN PPV 0.0048; SJS/TEN NPV 1.0000; DRESS PPV 0.0251; DRESS NPV 0.9997. 
**Colchicine maintained for 6 months due to prophylaxis flare rate 
***In excess of the number of people with gout in the UK 




Figure 1: Schematic representation of the decision analytic model. Patients in the ‘no test’ 
scenario all enter the model at A, whilst patients in the ‘test’ scenario enter the model in 
either A or B dependent upon test result. Patient flow between each 3-month model is 
represented at the leaf nodes. Where patients reach the Markov model (model D) before 
the end of 12-months, the first cycles (up until 12-months) are treated as the run in period. 
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Abbreviations: SJS Steven-Johnson syndrome, TEN toxic epidermal necrolysis, DRESS drug 






Figure 2: Tornado plot illustrating univariate sensitivity analysis. (L,H) and (H,L) indicate 
whether the range tested is displayed as low-high or high-low, respectively. The vertical line 
at £44,954 per QALY gained represents the ICER corresponding to the base case analysis. 
Abbreviations: sUA serum uric acid concentration, ICER incremental cost effectiveness ratio, 





Figure 3: Cost effectiveness acceptability curve indicating the probability of testing being 
cost-effective for a range of threshold values.  
Abbreviations: QALY quality-adjusted life-year 
 
